SOPHiA GENETICS has launched MSK-ACCESS® powered with SOPHiA DDM™!

This decentralized version of the highly validated liquid biopsy assay developed and routinely used by Memorial Sloan Kettering Cancer Center (MSK) uses a matched tumor-normal approach to reduce noise and the risk of biological false positives. By combining MSK’s clinical expertise in cancer genomics and the robust algorithms of the SOPHiA DDM™ Platform, we can support laboratories worldwide with their precision cancer analysis capabilities.

Learning Objectives:

Understand the advantages of using a matched tumor-normal approach to reduce noise and the risk of biological false positives.
Learn about the clinical implementation and benefits of MSK-ACCESS® at MSK and its evolution from version 1 to the expanded version 2.
Explore the analytical concordance data of MSK-ACCESS® powered with SOPHiA DDM™ for liquid biopsy.

Brian Loomis PhD

Director of Clinical Next-Generation Sequencing, Department of Pathology and Laboratory Medicine, MSK, Memorial Sloan Kettering Cancer Center

Appearances